AbbVie announces data from Phase 2 lymphocytic leukemia study
AbbVie announced new data from the Phase 2 Captivate clinical trial evaluating Imbruvica in combination with venetoclax in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Results showed that patients who received up to 12 cycles of the combination regimen achieved high rates of undetectable minimal residual disease in both peripheral blood and in bone marrow, the company said. Safety data were consistent with the known safety profiles of Imbruvica and venetoclax used as individual therapies, it added. The Phase 2 clinical trial evaluated 164 patients younger than 70 years with previously untreated CLL/SLL. 92% of patients were randomly assigned to receive Imbruvica monotherapy as lead-in treatment for three cycles. Results showed uMRD - defined as less than 1 CLL cell per 10,000 leukocytes by flow cytometry of PB or BM samples - was achieved at any time after baseline in PB for 75 percent of patients and in BM for 72%, AbbVie said.